Proactive Investors
26 May 2026, 11:45 UTC · 1h ago
Leading banks back Oxford Nanopore after London Calling showcases maturing platform
Source · https://www.proactiveinvestors.co.uk/companies/news/1092870
Read source
Search tags
Proactive Investors
26 May 2026, 11:45 UTC · 1h ago
Source · https://www.proactiveinvestors.co.uk/companies/news/1092870
Read sourceSearch tags
Story key points
5 claims · impact-rated
RBC Capital Markets and Citi have reiterated buy-equivalent ratings for Oxford Nanopore Technologies following its annual customer conference. — Positive analyst endorsements from major institutions typically drive investor confidence and buying pressure.
+0.60Oxford Nanopore is launching a new PromethION Plus flow cell that increases data output by 20% and lowers genome sequencing costs to roughly $400. — Improved cost-competitiveness and efficiency in a core product line enhance the company's market share potential.
+0.50The company has developed a first amino acid caller for protein sequencing, successfully identifying 22 E. coli proteins. — This represents a potential long-term technological leap into a new market segment (protein sequencing) beyond DNA.
+0.40Oxford Nanopore is expanding its biopharma partnerships with quality control workflows for mRNA vaccines, engaging partners like Moderna, Pfizer, and BioNTech. — Partnerships with global pharmaceutical giants validate the technology's commercial viability and recurring revenue potential.
+0.40The company has appointed new Chief Medical, Information, and People officers to strengthen operational capability and clinical applications. — Management upgrades suggest a shift toward operational scaling and clinical execution, though the immediate market impact is lower than product news.
+0.20Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
Received positive reviews and reiterated buy ratings from RBC Capital Markets and Citi following a successful customer conference.
A portfolio company is partnering to scale a bio-based alternative to ceramic tiles.
Mentioned as a partner working with Oxford Nanopore's technology.
Mentioned as a partner working with Oxford Nanopore's technology.
Mentioned as a partner working with Oxford Nanopore's technology.
[b_to_a] Dekiln is described as a Frontier IP Group PLC portfolio company.
[mutual] Pfizer is listed as a partner working with Oxford Nanopore's technology.
[mutual] BioNTech is listed as a partner working with Oxford Nanopore's technology.
[mutual] Moderna is listed as a partner working with Oxford Nanopore's technology.
[mutual] Regeneron is listed as a partner working with Oxford Nanopore's technology.